CDXS

CODEXIS, INC.

Nasdaq· Industrial Organic Chemicals· Inc. DE· CIK 0001200375 Biotech & Drug Discovery

$1.28 +0.00 (+0.39%)

Oct 26 4:00 PM ET · prev $1.28

Market cap

$143.5M

Micro cap

Consensus

Buy

79% Buy or better · 14 analysts

Median target

$5.00

+289% · range $2.00–11.00

Next earnings

Oct 29

in 3 days · EPS est. −$0.10

1 year

−50.6%

from $2.60 · Oct 27

30 days

−5.5%

from $1.36

52-week range

$0.9800–2.85

−55% from high · low Mar 3

Avg volume 20D

789.4K

shares / day

Short interest

4.84M

≈4.4% of shares · +20.2%

Days to cover

5.0

at average volume

Insider net

-$43.3K

0 buyers · 4 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BEARISH 3 reports · 90 days

Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 2/3 ·Next Earnings date, Oct 29, 2026

Strongest BEARISH Three institutional asset managers reduced or nearly exited their positions in Codexis during Q3 2026, with…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Feb 6 3 insiders sell $13.3K at $1.31
S Feb 24 1 insider sell $6.6K at $1.13
S Jun 11 1 insider sell $6.2K at $2.37
E Jul 24 Offering: Codexis Announces Pricing of Public Offering of Common Stock
R Jul 24 Codexis is offering 16,666,667 shares of common stock at $1.50 per s…
R Jul 24 Codexis priced a dilutive underwritten public offering of 16,666,667…
R Jul 27 Codexis closed a public offering of 16,666,667 shares of common stoc…
S Oct 12 2 insiders sell $17.2K at $1.36

Signal stack

Where each data set points today.

InsidersBEARISH

4 insiders sold $43.3K.
InstitutionsBULLISH

Q2 2026: 21 added (0 new), 10 trimmed or exited.
AnalystsBULLISH

11 of 14 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.085 → −$0.095 over 90 days. 1 up, 0 down in 30 days.
Short sellersBUILDING

Short interest +20.2% to 4.84M shares. 5.0 days to cover, ≈4.4% of shares.
TrendDOWNTREND

10% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
MILLENNIUM MANAGEMENT LLC	ADD	5,549,139	$12.5M
D. E. Shaw & Co., Inc.	ADD	1,342,014	$3.0M
VANGUARD PORTFOLIO MANAGEMENT LLC	ADD	1,307,171	$3.0M
Assenagon Asset Management S.A.	ADD	1,278,206	$2.9M
MORGAN STANLEY	ADD	649,170	$1.5M
GOLDMAN SACHS GROUP INC	TRIM	434,924	$982.9K
TUDOR INVESTMENT CORP ET AL	TRIM	357,925	$808.9K
Russell Investments Group, Ltd.	DOUBLED	308,095	$696.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts

Buy 79% rate it Buy or better

Strong Buy5Buy6Hold3Sell0Strong Sell0

12-month targets · 7 analysts

$1.28 $2.00 $5.00 $11.00

Price is below the lowest target. Median implies +289%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 17, 2026	Piper Sandler MAINTAIN	MAINTAIN	Overweight

Insider ledger

Form 4

bought · 0 insiders

$43.3K

sold · 4 insiders

Date	Insider	Type	Value
Oct 12, 2026	MOORE ALISON President and CEO	SELL	$8.6K
Oct 12, 2026	Erbez Georgia See Remarks	SELL	$8.6K
Jun 17, 2026	De Vre Raymond Director	AWARD	66,350 sh
Jun 17, 2026	DILLY STEPHEN GEORGE Director	AWARD	66,350 sh
Jun 17, 2026	Martinborough Esther Director	AWARD	66,350 sh
Jun 17, 2026	Singhvi Rahul Director	AWARD	66,350 sh
Jun 17, 2026	Smith David V Director	AWARD	66,350 sh
Jun 17, 2026	Richards Christos Director	AWARD	66,350 sh

Earnings setup

Estimates

Oct 29

reports in 3 days

−$0.10

EPS estimate, this quarter

−12%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.085

90d

−$0.085

60d

−$0.080

30d

−$0.080

−$0.095

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.10	-$0.11–-$0.08	-18.8%	$18.7M
Next Q	-$0.10	-$0.11–-$0.09	+9.1%	$25.0M
Current FY	-$0.42	-$0.43–-$0.42	-1.2%	$73.9M
Next FY	-$0.32	-$0.32–-$0.32	+0.0%	$87.7M

Short side

FINRA· Sep 30, 2026

4,839,321

shares short

+20.2%

vs prior settlement

5.0

days to cover

≈4.4%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 20, 2026 SEC

Three institutional asset managers reduced or nearly exited their positions in Codexis during Q3 2026, with aggregate…

INST-CLUSTER — Impact 4/10

Oct 13, 2026 SEC

Georgia Erbez, an officer of Codexis, filed a Form 144 notice of intent to sell 6,335 shares of common stock, valued…

144 — Impact 2/10

Oct 13, 2026 SEC

Director Alison Moore filed a Form 144 notice of intent to sell 6,335 shares of Codexis common stock, valued at…

144 — Impact 2/10

Oct 12, 2026 Insider

MOORE ALISON sold 6,335 shares

President and CEO @ $1.36 ($8.6K)

Oct 12, 2026 Insider

Erbez Georgia sold 6,335 shares

See Remarks @ $1.36 ($8.6K)

Sep 30, 2026 Short interest report

Short Interest: CDXS up 20% to 4.8M shares

Settlement 2026-09-30 | Days to cover: 5.00 | ≈4.42% of shares outstanding (est.)

Jul 23, 2026 Press

Codexis priced a dilutive underwritten public offering of 16,666,667 shares at $1.50/share, expected to raise ~$23.1M…

Impact 6/10

Jun 30, 2026 Inst.

MILLENNIUM MANAGEMENT LLC — ADD

5,549,139 shares ($12.5M)

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Oct 29, 2026

Earnings date

CDXS Q3 2026 Earnings Scheduled — 2026-10-29

Recent

Sep 30, 2026

Short interest

Short Interest: CDXS up 20% to 4.8M shares

Settlement 2026-09-30 | Days to cover: 5.00 | ≈4.42% of shares outstanding (est.)

Sep 28, 2026

Press release

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and…

Aug 11, 2026

Earnings date

CDXS Q2 2026 Earnings Scheduled — 2026-08-11

Jul 30, 2026

Earnings date

CDXS Q2 2026 Earnings Scheduled — 2026-07-30

Jul 23, 2026

Offering

Codexis Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and…